Equity · Healthcare
BBOT
NASDAQBridgeBio Oncology Therapeutics (BBOT)
The line runs 9.43 USD on 12 August through 2.31 USD on 9 November, on a scale from 2 to 10. Days the market did not trade hold the previous close, flat.
- Market cap
- 185.2M USD
- EPS, diluted, year to Dec 2025
- −4.30 USD
- Avg volume
- 46.5K
as of Nov 9, 2026
Have BridgeBio Oncology Therapeutics (BBOT) insiders bought or sold shares recently?
In the 90 days to 10 Nov 2026, no BridgeBio Oncology Therapeutics insider bought or sold shares on the open market; all 7 Form 4 filings in that window were grants, exercises, tax withholding or transfers (SEC Form 4).
Form 4, 90 days to 10 Nov 2026, newest Form 4 filing 21 Oct 2026
| Reported | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 21 Oct 2026 | Cobo MarcPrincipal Accounting Officer | Tax withheld | 203 | 544 USD |
| 01 Oct 2026 | Cobo MarcPrincipal Accounting Officer | Tax withheld | 126 | 496 USD |
| 01 Oct 2026 | Elmelech IdanCOO & Principal Financial Ofcr | Tax withheld | 343 | 1K USD |
| 01 Oct 2026 | Beltran PedroPresident and CEO | Tax withheld | 1,047 | 4K USD |
| 01 Oct 2026 | Ben YongChief Med & Dev Officer | Tax withheld | 1,047 | 4K USD |
| 10 Sep 2026 | Cobo MarcPrincipal Accounting Officer | Award | 9,038 | |
| 10 Sep 2026 | Cobo MarcPrincipal Accounting Officer | Tax withheld | 203 | 1K USD |
Which funds hold BridgeBio Oncology Therapeutics (BBOT)?
4 of the 45 institutional funds we track reported a BridgeBio Oncology Therapeutics position for the quarter ended 30 Jun 2026 — a combined 21.4M USD; the latest of those filings landed 02 Sep 2026.
| Fund | Position | Shares | Value | Shares q/q |
|---|---|---|---|---|
| Citadel Advisors | Held (±25%) | 2,617,827 | 19.9M USD | +3.5% |
| Millennium Management | Trimmed | 105,480 | 804K USD | −60.3% |
| Renaissance Technologies | Trimmed | 58,600 | 447K USD | −42.5% |
| Two Sigma Investments | New position | 26,485 | 202K USD |
What has been filed or recorded for BridgeBio Oncology Therapeutics (BBOT)?
The filings we hold for BridgeBio Oncology Therapeutics, newest first: 1 fails-to-deliver day, 6 quarterly earnings reports, 2 annual reports and 4 reported financial figures, the latest dated 02 Oct 2026. No next earnings date is announced in SEC filings yet.
| And | ||||
|---|---|---|---|---|
| 02 Oct 2026 | Fails to deliver | Shares failed to deliver | 2,988 shares | 12K USD notional · 0.004% of shares out |
| 30 Jun 2026 | Quarterly earnings | Q2 2026 reported | EPS −705.20 USD | |
| 30 Jun 2026 | Financials | Total assets | 376.7M USD | at period end |
| 30 Jun 2026 | Financials | Total equity | 323.1M USD | at period end |
| 31 Mar 2026 | Quarterly earnings | Q1 2026 reported | EPS −526.11 USD | |
| 31 Dec 2025 | Annual report | FY 2025 reported | EPS −4.30 USD | |
| 31 Dec 2025 | Financials | Net income | −134.0M USD | fiscal year |
| 31 Dec 2025 | Financials | Diluted EPS | −4.30 USD | fiscal year |
| 30 Sep 2025 | Quarterly earnings | Q3 2025 reported | EPS −1.03 USD | |
| 30 Jun 2025 | Quarterly earnings | Q2 2026 reported | EPS −566.46 USD | |
| 31 Mar 2025 | Quarterly earnings | Q1 2026 reported | EPS −54.23 USD | |
| 31 Dec 2024 | Annual report | FY 2025 reported | EPS −5,756.41 USD | |
| 30 Sep 2024 | Quarterly earnings | Q3 2025 reported | EPS −1,562.18 USD |
What do people ask about BridgeBio Oncology Therapeutics (BBOT)?
What did BridgeBio Oncology Therapeutics shares close at?2.31
BridgeBio Oncology Therapeutics closed at 2.31 USD on 9 Nov 2026, up 13.79% on the close before. That is the end-of-day price from Finazon, not a live quote.
What is BridgeBio Oncology Therapeutics’ market cap?185.2M
BridgeBio Oncology Therapeutics is worth 185.2M USD by market value as of 9 Nov 2026, which is the share price times the shares on issue from its SEC filings.
Have BridgeBio Oncology Therapeutics insiders bought or sold shares recently?7 filings
In the 90 days to 10 Nov 2026, no BridgeBio Oncology Therapeutics insider bought or sold shares on the open market; all 7 Form 4 filings in that window were grants, exercises, tax withholding or transfers (SEC Form 4). See Insiders
Which funds own BridgeBio Oncology Therapeutics?4 of 45
4 of the 45 funds we track reported a BridgeBio Oncology Therapeutics position for the quarter ended 30 Jun 2026, per their SEC Form 13F filings. The largest reported positions were Citadel Advisors, Millennium Management and Renaissance Technologies. See Funds
When did BridgeBio Oncology Therapeutics last report earnings?−705.20
BridgeBio Oncology Therapeutics last reported earnings on 30 Jun 2026 for Q2 2026, with EPS of −705.20 USD; no next date is announced in SEC filings yet. See Filings
Answers are generated from the live figures on this page — Reddit crowd data, SEC filings and open company records — and update as the data does.
References
- Finazonprior-day close, indicative (IEX-derived, not the official close), some closes dollar-rounded at the source
- TradingViewthe price chart widget, drawn by TradingView from their own data
- SEC EDGARForm 4 filings (insider transactions)
- SEC EDGAR13F filings
- SECSEC fails-to-deliver (CNS) data
- SEC EDGARXBRL company facts, latest period ended 30 Jun 2026
- SEC EDGARreported earnings figures and scheduled report dates
- SEC EDGARValuation computed from SEC EDGAR filings